Who are HX575 epoetin alfa Hexal AG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epogen, ARM A : IV iron + epoietin zeta, Erythropoietins (EPO), ARM B: IV iron + epoietin zeta sequence, Vifor and EPO, recomon (Epoetin Beta).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hx575-epoetin-alfa-hexal-ag.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HX575 epoetin alfa Hexal AG — Competitive Intelligence Brief

HX575 epoetin alfa Hexal AG (HX575 epoetin alfa Hexal AG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA); biosimilar. Area: Hematology/Oncology.

phase 3 Erythropoiesis-stimulating agent (ESA); biosimilar Erythropoietin receptor (EPOR) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HX575 epoetin alfa Hexal AG (HX575 epoetin alfa Hexal AG) — Sandoz. HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HX575 epoetin alfa Hexal AG TARGET	HX575 epoetin alfa Hexal AG	Sandoz	phase 3	Erythropoiesis-stimulating agent (ESA); biosimilar	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Erythropoietins (EPO)	Erythropoietins (EPO)	Shanghai East Hospital	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
recomon (Epoetin Beta)	recomon (Epoetin Beta)	JW Pharmaceutical	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA); biosimilar class)

Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HX575 epoetin alfa Hexal AG — Competitive Intelligence Brief. https://druglandscape.com/ci/hx575-epoetin-alfa-hexal-ag. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab